Skip NavigationSkip to Content
Return Return to Search Results

Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: Interferon induces HR independent of sustained virologic response (SVR)

  1. Author:
    Wu, L.
    Kottilil, S.
    Lempicki, R.
    Yang, J.
    McLaughlin, M.
    Hu, Z. H.
    Koratich, C.
    Reitano, K. N.
    Rehm, C. A.
    Masur, H.
    Wood, B.
    Kleiner, D. E.
    Polis, M. A.

  2. Author Address

    NIAID, LIR, Immunopathogenesis Sect, NIH,DHHS,Lab Immunoregulat, Bethesda, MD 20892 USA. NCI, SAIC, Frederick, MD 21701 USA. NIAID, Biostat Res Branch, NIH, DHHS, Bethesda, MD 20892 USA. NIH, Dept Crit Care Med, CC, DHHS, Bethesda, MD 20892 USA. NIH, Dept Diagnost Radiol, DHHS, CC, Bethesda, MD 20892 USA. NCI, NIH, DHHS, Bethesda, MD 20892 USA.;Kottilil, S, NIAID, LIR, Immunopathogenesis Sect, NIH,DHHS,Lab Immunoregulat, Bldg 10 Rm 11N204,9000 Rockville Pike, Bethesda, MD 20892 USA.;Skottilil@niaid.nih.gov
    1. Year: 2006
    2. Date: Nov
  2. Journal: Aids Research and Human Retroviruses
    1. 22
    2. 11
    3. Pages: 1091-1098
  4. Type of Article: Article
  5. ISSN: 0889-2229
  1. Abstract:

    Most HIV/HCV-coinfected patients fail to achieve a sustained virologic response (SVR) to peginterferon-ribavirin therapy. We examined the hepatic histologic response (HR), defined as an improvement in hepatic inflammation scores of two points or more, to combination therapy among HIV/HCV-coinfected subjects. An open label prospective trial treated 32 HIV/HCV-coinfected patients with peginterferon alpha-2b and ribavirin for 48 weeks. Liver biopsies, scored by a single pathologist using the Histology Activity Index (HAI, range 0 - 18) and Ishak fibrosis scores ( range 0 - 6), were performed before and after treatment. Gene expression profiles of PBMCs were performed using Affymetrix U133A gene chips. A total of 87% of SVR subjects and 88% of nonresponders (NR) had an HR, but no significant change in the liver fibrosis scores was observed ( p > 0.05). For genotype 1 patients, a baseline fibrosis score <= 2 was related to a higher likelihood of SVR than those with a score > 2 ( p = 0.012). Combination therapy for HCV among HIV-coinfected subjects resulted in a modest SVR rate. Persons with mild liver disease had a better SVR rate, suggesting early treatment may be beneficial. Combination therapy resulted in an HR for most of the patients, however, further follow-up of these patients will determine the durability of such an HR.

    See More

  1. Keywords:

External Sources

  1. View record in Web of Science®
  2. WOS: 000242770700005

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel